Enhancing Endocannabinoid Control of Stress with Cannabidiol.
Field | Value | Language |
dc.contributor.author | Henson, Jeremy D | |
dc.contributor.author | Vitetta, Luis | |
dc.contributor.author | Quezada, Michelle | |
dc.contributor.author | Hall, Sean | |
dc.date.accessioned | 2022-08-24T05:09:17Z | |
dc.date.available | 2022-08-24T05:09:17Z | |
dc.date.issued | 2021 | en_AU |
dc.identifier.uri | https://hdl.handle.net/2123/29459 | |
dc.description.abstract | The stress response is a well-defined physiological function activated frequently by life events. However, sometimes the stress response can be inappropriate, excessive, or prolonged; in which case, it can hinder rather than help in coping with the stressor, impair normal functioning, and increase the risk of somatic and mental health disorders. There is a need for a more effective and safe pharmacological treatment that can dampen maladaptive stress responses. The endocannabinoid system is one of the main regulators of the stress response. A basal endocannabinoid tone inhibits the stress response, modulation of this tone permits/curtails an active stress response, and chronic deficiency in the endocannabinoid tone is associated with the pathological complications of chronic stress. Cannabidiol is a safe exogenous cannabinoid enhancer of the endocannabinoid system that could be a useful treatment for stress. There have been seven double-blind placebo controlled clinical trials of CBD for stress on a combined total of 232 participants and one partially controlled study on 120 participants. All showed that CBD was effective in significantly reducing the stress response and was non-inferior to pharmaceutical comparators, when included. The clinical trial results are supported by the established mechanisms of action of CBD (including increased N-arachidonylethanolamine levels) and extensive real-world and preclinical evidence of the effectiveness of CBD for treating stress. | en_AU |
dc.language.iso | en | en_AU |
dc.publisher | MDPI | en_AU |
dc.relation.ispartof | Journal of Clinical Medicine | en_AU |
dc.rights | Creative Commons Attribution 4.0 | en_AU |
dc.subject | AEA | en_AU |
dc.subject | CBD | en_AU |
dc.subject | N-arachidonylethanolamine | en_AU |
dc.subject | cannabidiol | en_AU |
dc.subject | endocannabinoid | en_AU |
dc.subject | hypothalamus–pituitary–adrenal axis; | en_AU |
dc.subject | stress | en_AU |
dc.title | Enhancing Endocannabinoid Control of Stress with Cannabidiol. | en_AU |
dc.type | Article | en_AU |
dc.subject.asrc | 0304 Medicinal and Biomolecular Chemistry | en_AU |
dc.identifier.doi | 10.3390/jcm10245852 | |
dc.type.pubtype | Publisher's version | en_AU |
usyd.faculty | SeS faculties schools::Faculty of Medicine and Health::The University of Sydney School of Pharmacy | en_AU |
usyd.citation.volume | 10 | en_AU |
usyd.citation.issue | 24 | en_AU |
usyd.citation.spage | 5852 | en_AU |
workflow.metadata.only | No | en_AU |
Associated file/s
Associated collections